AlloVir Inc. (ALVR) News
Filter ALVR News Items
ALVR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ALVR News From Around the Web
Below are the latest news stories about ALLOVIR INC that investors may wish to consider to help them evaluate ALVR as an investment opportunity.
AlloVir and Kalaris enter merger to advance retinal disease therapiesThe combined entity will operate as Kalaris Therapeutics, with approximately $100m in cash reserves. |
Kalaris to go public via reverse merger with AlloVirAfter Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. |
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the RetinaKalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful advance in treatment in the global $1 |
Discovering Opportunities: AlloVir And 2 Other US Penny StocksAs the U.S. stock market navigates a landscape shaped by mixed economic data and ongoing corporate earnings reports, investors are keenly observing potential opportunities across various sectors. Penny stocks, a term that may seem outdated, still capture the essence of investing in smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover hidden gems amidst these lesser-known equities. |
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Are Medical Stocks Lagging AlloVir (ALVR) This Year?Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year. |